- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - MOUNTAIN VIEW, Calif. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq Stockholm:

MOUNTAIN VIEW, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences , Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at the 39th Annual J.P.